Differentiating Types of Arthritis: A Brief Overview

Arthritis is a common condition that affects millions of people worldwide. However, not all types of arthritis are the same. Here is a brief overview of some of the most common types of arthritis and how they differ from each other.

Psoriatic Arthritis: This type of arthritis is often seen in people with psoriasis and is characterized by painful, swollen joints. Dactylitis, or swelling of the whole digit causing ‘sausage-shaped’ fingers or toes, is a common feature. Nail changes, such as pitting and onycholysis, are also associated with psoriatic arthritis.

Gonococcal Arthritis: This is a type of septic arthritis caused by the sexually transmitted infection Neisseria gonorrhoeae. It typically presents with fever, a rash, and an acutely swollen joint, but there is no nail involvement.

Osteoarthritis (OA): This is a disease of synovial joints in which there is a loss of cartilage. It is uncommon for OA to be diagnosed in anyone under the age of 45. Dactylitis and nail changes are not associated with OA.

Reactive Arthritis: This is a sterile arthritis occurring following an infection, usually either an acute gastrointestinal or sexually transmitted infection. The clinical features of dactylitis and nail changes described in this case are not associated with reactive arthritis.

Rheumatoid Arthritis (RA): This is an inflammatory condition that tends to affect the small joints of the hands but can affect any synovial joint. Nail changes are not usually associated with RA, and general swelling of the whole digit (dactylitis) is not a typical feature.

In conclusion, understanding the different types of arthritis and their unique features is important for accurate diagnosis and appropriate treatment.

Neonatal Blood Spot Screening: Identifying Potential Health Risks in Newborns

Neonatal blood spot screening, also known as the Guthrie test or heel-prick test, is a routine procedure performed on newborns between 5-9 days of life. The test involves collecting a small sample of blood from the baby’s heel and analyzing it for potential health risks. Currently, there are nine conditions that are screened for, including congenital hypothyroidism, cystic fibrosis, sickle cell disease, phenylketonuria, medium chain acyl-CoA dehydrogenase deficiency (MCADD), maple syrup urine disease (MSUD), isovaleric acidaemia (IVA), glutaric aciduria type 1 (GA1), and homocystinuria (pyridoxine unresponsive) (HCU).

Ankylosing spondylitis is a type of spondyloarthropathy that is associated with HLA-B27. It is more commonly seen in young males, with a sex ratio of 3:1, and typically presents with lower back pain and stiffness that develops gradually. The stiffness is usually worse in the morning and improves with exercise, while pain at night may improve upon getting up. Clinical examination may reveal reduced lateral and forward flexion, as well as reduced chest expansion. Other features associated with ankylosing spondylitis include apical fibrosis, anterior uveitis, aortic regurgitation, Achilles tendonitis, AV node block, amyloidosis, cauda equina syndrome, and peripheral arthritis (more common in females).

Unilateral nasal polyps are a cause for concern and should be promptly referred to an ENT specialist as they may indicate nasal cancer. However, they can also be caused by other factors such as nose picking, foreign bodies, misapplication of nasal spray or cystic fibrosis. Treatment with antibiotics, oral steroids, nasal drops or cautery is unlikely to be effective and may delay the diagnosis of a serious condition.

Understanding Nasal Polyps

Nasal polyps are a relatively uncommon condition affecting around 1% of adults in the UK. They are more commonly seen in men and are not typically found in children or the elderly. There are several associations with nasal polyps, including asthma (particularly late-onset asthma), aspirin sensitivity, infective sinusitis, cystic fibrosis, Kartagener’s syndrome, and Churg-Strauss syndrome. When asthma, aspirin sensitivity, and nasal polyposis occur together, it is known as Samter’s triad.

The symptoms of nasal polyps include nasal obstruction, rhinorrhoea, sneezing, and a poor sense of taste and smell. It is important to note that any unusual symptoms, such as unilateral symptoms or bleeding, require further investigation. If nasal polyps are suspected, patients should be referred to an ear, nose, and throat (ENT) specialist for a full examination.

The management of nasal polyps typically involves the use of topical corticosteroids, which can shrink polyp size in around 80% of patients. Overall, understanding nasal polyps and their associations can help with early detection and appropriate management.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

According to NICE guidelines (2019), if a beta-blocker is not effectively controlling angina, a long-acting dihydropyridine calcium-channel blocker (CCB) like amlodipine should be added. It is important to ensure that the patient is taking the highest tolerated dose of their current medications before adding new ones.

Ramipril is not the best treatment option for this patient as there is no evidence of hypertension in their medical history. While ACE inhibitors like ramipril can be effective in preventing myocardial infarction and stroke in patients with angina and hypertension, they are not indicated in this case.

Verapamil is a CCB that can be used to manage angina, but it should not be used in combination with a beta-blocker as this can increase the risk of severe bradycardia and heart failure.

As the patient is not displaying any signs of unstable angina, such as pain at rest or rapidly progressing symptoms, admission to the emergency department is not necessary.

If there is evidence of extensive ischaemia on an electrocardiograph (ECG) or the patient is not responding well to an optimised drug treatment, referral to cardiology for angioplasty may be necessary.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

For an adult with asthma that is not controlled by a short-acting beta-agonist, the appropriate next step is to add a low-dose inhaled corticosteroid. This is in accordance with NICE guidelines. The addition of a combined inhaled corticosteroid and long-acting beta-agonist is not recommended until symptoms cannot be controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist. Similarly, a leukotriene receptor antagonist or long-acting beta-agonist should not be introduced until symptoms are not controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

Understanding Addison’s Disease: Hormonal Imbalances and Clinical Presentation

Addison’s disease, or primary adrenal failure, is a condition characterized by autoimmune destruction of the adrenal cortex, resulting in reduced levels of cortisol and aldosterone. This hormonal imbalance leads to a range of clinical symptoms, including hypotension, hyponatraemia, hyperkalaemia, acidosis, and skin and mucosal hyperpigmentation.

While other hormonal imbalances may occur in the adrenal glands, such as increased cortisol or aldosterone, they are less likely to result in the clinical presentation of Addison’s disease. For example, increased cortisol is unlikely due to autoimmune destruction of the zona fasciculata, while increased aldosterone is rare and typically caused by an adrenal adenoma. Similarly, decreased cortisol with normal aldosterone is more commonly associated with secondary adrenal failure caused by pituitary disease, but does not fit with the hyponatraemia seen in Addison’s disease.

Overall, understanding the hormonal imbalances and clinical presentation of Addison’s disease is crucial for accurate diagnosis and effective treatment.

Understanding Sarcoidosis: A Multisystem Disorder

Sarcoidosis is a condition that affects multiple systems in the body and is characterized by the presence of non-caseating granulomas. Although the exact cause of sarcoidosis is unknown, it is more commonly seen in young adults and people of African descent.

The symptoms of sarcoidosis can vary depending on the severity of the condition. Acute symptoms may include erythema nodosum, bilateral hilar lymphadenopathy, swinging fever, and polyarthralgia. On the other hand, insidious symptoms may include dyspnea, non-productive cough, malaise, and weight loss. In some cases, sarcoidosis can also cause skin lesions such as lupus pernio and hypercalcemia due to increased conversion of vitamin D to its active form.

Sarcoidosis can also present as different syndromes. Lofgren’s syndrome is an acute form of the disease characterized by bilateral hilar lymphadenopathy, erythema nodosum, fever, and polyarthralgia. It usually has a good prognosis. Mikulicz syndrome, which is now considered outdated and unhelpful by many, is characterized by enlargement of the parotid and lacrimal glands due to sarcoidosis, tuberculosis, or lymphoma. Heerfordt’s syndrome, also known as uveoparotid fever, is characterized by parotid enlargement, fever, and uveitis secondary to sarcoidosis.

In conclusion, sarcoidosis is a complex condition that affects multiple systems in the body. Understanding the different symptoms and syndromes associated with sarcoidosis can help in the diagnosis and management of this condition.

Screening for Hepatocellular Carcinoma: Recommended Tests and Intervals

Regular screening for hepatocellular carcinoma (HCC) is recommended in high-risk patients. Abdominal ultrasound (US) is the primary screening tool, with 6-month intervals for follow-up if a lesion of < 1 cm is detected. If there is no growth over 1-2 years, routine 6-monthly surveillance can continue. Alpha-fetoprotein (AFP) levels may be used in conjunction with US, but are not reliable on their own. A triphasic contrast computed tomography (CT) scan is recommended every two years for high-suspicion cases. This article provides an overview of the recommended tests and intervals for HCC screening.

Understanding Hypokalaemia and its Features

Hypokalaemia is a medical condition characterized by low levels of potassium in the blood. It can lead to various symptoms, including muscle weakness and hypotonia. Patients with hypokalaemia who are also taking diuretics should be monitored closely for digoxin toxicity.

One of the most significant concerns with hypokalaemia is its impact on the heart. ECG features associated with hypokalaemia include U waves, small or absent T waves, prolonged PR interval, and ST depression. These changes can increase the risk of arrhythmias and other cardiac complications.

It is essential to recognize the signs and symptoms of hypokalaemia promptly. Treatment may involve potassium supplements or addressing the underlying cause of the condition. With proper management, patients with hypokalaemia can avoid complications and improve their overall health.

Diagnosis and Investigation of Immune Thrombocytopenic Purpura (ITP)

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by antiplatelet antibodies and immune-mediated platelet destruction, leading to a decrease in peripheral platelet count and an increased risk of severe bleeding. The following are the recommended diagnostic and investigative measures for ITP:

Full Blood Count: An urgent first-line investigation with a full blood count is essential to confirm platelet count, which is the hallmark of ITP. Anaemia and/or neutropenia may indicate other diseases. On peripheral blood smear, the morphology of red blood cells and leukocytes is normal, while the morphology of platelets is usually normal, with varying numbers of large platelets.

Surgical Correction: Surgical management is not the first-line intervention for ITP and is reserved for later use in patients with acute ITP, for whom splenectomy usually results in rapid, complete, and life-long clinical remission. Its results in patients with chronic ITP are typically less predictable.

Aspiration for Cytology: Further investigations, such as bone marrow aspiration, could be considered for later use in patients with ITP, such as adults older than 60 years, to exclude myelodysplastic syndrome or leukemia.

Excision Biopsy: Further investigations, such as a biopsy, could be considered further down the line, such as in adults older than 60 years, to exclude myelodysplastic syndrome or leukemia.

None: If a patient presents with purpura/petechiae on the tongue and buccal mucosa, urgent haematological referral is warranted, and not undertaking any further investigations would be inappropriate.

Diagnosis and Investigation of Immune Thrombocytopenic Purpura (ITP)

Oral terbinafine is recommended for treating dermatophyte nail infections.

Understanding Fungal Nail Infections

Fungal nail infections, also known as onychomycosis, can affect any part of the nail or the entire nail unit. However, toenails are more susceptible to infection than fingernails. The primary cause of fungal nail infections is dermatophytes, with Trichophyton rubrum being the most common. Yeasts, such as Candida, and non-dermatophyte moulds can also cause fungal nail infections. Risk factors include increasing age, diabetes mellitus, psoriasis, and repeated nail trauma.

The most common symptom of fungal nail infections is unsightly nails, which can be thickened, rough, and opaque. Other conditions, such as psoriasis, repeated trauma, lichen planus, and yellow nail syndrome, can mimic fungal nail infections. To confirm a diagnosis, nail clippings and scrapings of the affected nail should be examined under a microscope and cultured.

Asymptomatic fungal nail infections do not require treatment unless the patient is bothered by the appearance. However, if a dermatophyte or Candida infection is confirmed, treatment is necessary. Topical treatment with amorolfine 5% nail lacquer is recommended for limited involvement, while oral terbinafine is the first-line treatment for more extensive dermatophyte infections. Candida infections are best treated with oral itraconazole using a pulsed weekly therapy approach. It is important to note that cultures have a false-negative rate of around 30%, so repeat samples may be necessary if clinical suspicion is high.

Understanding Autosomal-Recessive Inheritance and Phenylketonuria (PKU)

Autosomal-recessive diseases require both parents to carry the gene, with one parent having the disease and the other being a carrier. In the case of Phenylketonuria (PKU), a specific enzyme deficiency leads to the accumulation of phenylalanine and a deficiency of tyrosine, resulting in reduced melanin and pigmented areas of the brain being affected. PKU is tested for at birth using the Guthrie test and can be treated by removing phenylalanine from the diet.

In the given scenario, the teenager’s mother has the disease and his father is a carrier. This means there is a 100% chance that the teenager has at least one abnormal copy of the gene, making him a carrier. It is important to understand the inheritance pattern of autosomal-recessive diseases to identify carriers and prevent mental retardation in affected children.

Common Genetic Disorders and Their Prenatal Ultrasound Findings

Prenatal ultrasound is a valuable tool for detecting genetic disorders in fetuses. Here are some common genetic disorders and their associated ultrasound findings:

1. Patau Syndrome (Trisomy 13): This disorder has a prevalence of 1 per 6500 births. Fetuses with Trisomy 13 may show brain anomalies, midfacial hypoplasia, ventriculomegaly, microcephaly, cleft lip and palate, and cardiac defects.

2. Cystic Fibrosis (CF): Hyperechogenic fetal bowel is often associated with severe diseases, notably CF.

3. Down Syndrome: 20% of all second-trimester Down syndrome fetuses have major structural anomalies, including polyhydramnios, double bubble, and large cardiac septal defects.

4. Klinefelter Syndrome: This disorder results from two or more X chromosomes in boys and may cause infertility and small testicles.

5. Potter Syndrome: This disorder is suspected whenever the combination of intrauterine growth retardation and severe oligohydramnios is seen. It consists of pulmonary hypoplasia, growth restriction, abnormal facies, and limb abnormalities.

In conclusion, prenatal ultrasound can help detect genetic disorders in fetuses, allowing for early intervention and management.

Possible Causes of Jaundice in a Breastfed Baby: Excluding Cystic Fibrosis, Galactosaemia, ABO Incompatibility, and Hypothyroidism

Breastmilk jaundice is a common cause of jaundice in healthy, breastfed babies beyond two weeks of age. However, other potential causes should still be screened for. The exact mechanism of breastmilk jaundice is unknown, but breastfeeding should continue and bilirubin levels should be monitored. If levels are above the treatment line, phototherapy may be necessary. Jaundice can persist for up to 12 weeks in some cases. Cystic fibrosis is excluded as a diagnosis if the newborn blood-spot test is normal. Galactosaemia is unlikely if the baby has not shown symptoms such as difficulty feeding, vomiting, and faltering growth. ABO incompatibility typically presents within the first 24 hours of life, so it is unlikely if symptoms appear eight days after birth. Hypothyroidism is screened for in the newborn blood-spot test, and normal results exclude it as a diagnosis.

Medication and Tinnitus: Understanding the Association

Tinnitus, the perception of sounds in the ears or head without an external source, can be distressing and may indicate an underlying condition. While it is often considered a minor symptom, certain medications have been associated with tinnitus. Quinine, commonly used to treat malaria, is one such medication. Other medications that may cause tinnitus include aspirin, aminoglycosides, loop diuretics, and non-steroidal anti-inflammatory drugs. However, medications like spironolactone, salbutamol, metformin, and nifedipine are not associated with tinnitus. It is important to understand the potential side effects of medications and to consult with a healthcare provider if experiencing tinnitus or any other concerning symptoms.

The symptoms exhibited by this patient are indicative of allergic conjunctivitis. The initial treatment approach for this condition involves the use of topical antihistamines. In case of additional symptoms like rhinosinusitis, oral antihistamines may also be prescribed.

Understanding Allergic Conjunctivitis

Allergic conjunctivitis is a condition that can occur on its own, but is often associated with hay fever. It is characterized by bilateral symptoms such as conjunctival erythema and swelling, as well as itchiness and swelling of the eyelids. Those with a history of atopy may be more prone to developing allergic conjunctivitis, which can be seasonal (due to pollen) or perennial (due to exposure to dust mites, washing powder, or other allergens).

When it comes to managing allergic conjunctivitis, first-line treatment typically involves the use of topical or systemic antihistamines. If these prove ineffective, second-line treatment options such as topical mast-cell stabilizers like Sodium cromoglicate and nedocromil may be recommended. By understanding the symptoms and treatment options for allergic conjunctivitis, individuals can take steps to manage their condition and reduce discomfort.

Warfarin should be continued indefinitely due to the patient’s risk factors for stroke and history of atrial fibrillation. It is preferred over direct oral anticoagulants due to his valvular heart disease.

NICE recommends using the CHA2DS2-VASc score to determine the need for anticoagulation in patients with any history of AF. The ORBIT scoring system should be used to assess bleeding risk, but anticoagulation should not be withheld solely on the grounds of age or risk of falls. DOACs are now recommended as the first-line anticoagulant for patients with AF, with warfarin used second-line if a DOAC is contraindicated or not tolerated. Aspirin is not recommended for reducing stroke risk in patients with AF.

A renal biopsy should only be considered if the response to steroids is inadequate.

Minimal change disease is a condition that typically presents as nephrotic syndrome, with children accounting for 75% of cases and adults accounting for 25%. While most cases are idiopathic, around 10-20% have a known cause, such as certain drugs, Hodgkin’s lymphoma, thymoma, or infectious mononucleosis. The pathophysiology of the disease involves T-cell and cytokine-mediated damage to the glomerular basement membrane, resulting in polyanion loss and reduced electrostatic charge, which increases glomerular permeability to serum albumin. The disease is characterized by nephrotic syndrome, normotension (hypertension is rare), and highly selective proteinuria, with only intermediate-sized proteins such as albumin and transferrin leaking through the glomerulus. Renal biopsy shows normal glomeruli on light microscopy, but electron microscopy reveals fusion of podocytes and effacement of foot processes.

Management of minimal change disease typically involves oral corticosteroids, which are effective in 80% of cases. For steroid-resistant cases, cyclophosphamide is the next step. The prognosis for the disease is generally good, although relapse is common. Approximately one-third of patients have just one episode, one-third have infrequent relapses, and one-third have frequent relapses that stop before adulthood.

The treatment of tuberculosis is a complex process that requires the expertise of a specialist in the field, such as a respiratory physician or an infectivologist. The first-line drugs used for active tuberculosis without CNS involvement are isoniazid, rifampicin, pyrazinamide, and ethambutol. These drugs are given together for the first 2 months of therapy, followed by continued treatment with just isoniazid and rifampicin for an additional 4 months. Pyridoxine is added to the treatment regimen to reduce the risk of isoniazid-induced peripheral neuropathy. If there is CNS involvement, the four drugs (and pyridoxine) are given together for 2 months, followed by continued treatment with isoniazid (with pyridoxine) and rifampicin for an additional 10 months. It is important to monitor liver function tests before and during treatment, and to educate patients on the potential side effects of the drugs and when to seek medical attention. Treatment-resistant tuberculosis cases are becoming more common and require special management and public health considerations.

Understanding Dermatomes: Major Landmarks and Mnemonics

Dermatomes are areas of skin that are innervated by a single spinal nerve. Understanding dermatomes is important in diagnosing and treating various neurological conditions. The major dermatome landmarks are listed with helpful mnemonics to remember them.

Starting from the top of the body, the C2 dermatome covers the posterior half of the skull, resembling a cap. Moving down to C3, it covers the area of a high turtleneck shirt. C4 covers the area of a low-collar shirt. The C5 dermatome runs along the ventral axial line of the upper limb, while C6 covers the thumb and index finger. To remember this, make a 6 with your left hand by touching the tip of the thumb and index finger together.

Moving down to C7, it covers the middle finger and palm of the hand. C8 covers the ring and little finger. The T4 dermatome covers the area of the nipples, while T5 covers the inframammary fold. T6 covers the xiphoid process, and T10 covers the umbilicus. To remember this, think of BellybuT-TEN.

The L1 dermatome covers the inguinal ligament, which can be remembered by thinking of L for ligament, 1 for 1nguinal. L4 covers the knee caps, and to remember this, think of being down on all fours. L5 covers the big toe and dorsum of the foot (except the lateral aspect), and can be remembered by thinking of it as the largest of the five toes. Finally, the S1 dermatome covers the lateral foot and small toe, while S2 and S3 cover the genitalia.

Understanding dermatomes and their landmarks can aid in diagnosing and treating various neurological conditions. The mnemonics provided can help in remembering these important landmarks.

Diagnostic Tests and Treatment for HIV-Associated Nephropathy

HIV infection is a high possibility in a patient with risk factors and presenting with emaciation, oral ulcers, and lymphopenia. HIV serological testing and a CD4 count should be done urgently to establish the diagnosis. HIV-associated nephropathy is a common complication, with focal and segmental glomerulosclerosis being the most frequent pathological diagnosis. Other variants include membranoproliferative nephropathy, diffuse proliferative glomerulonephritis, minimal change disease, and IgA nephropathy. Treatment involves angiotensin-converting enzyme inhibitors and antiretroviral therapy. Renal biopsy may be necessary, but HIV testing should be performed first. Serum complement levels and anti-nuclear factor may be useful in diagnosing SLE-associated nephropathy or other connective tissue diseases, but the lack of systemic symptoms in this case makes it less likely. Serum IgA levels may be elevated in IgA nephropathy, but it typically presents with haematuria rather than proteinuria.

Bone marrow suppression, which can be fatal, is a potential risk associated with the use of azathioprine as a second-line treatment for Crohn’s disease. Budesonide, a corticosteroid medication primarily used for asthma prevention, may be considered as a second-line option for inducing remission in Crohn’s patients. Mesalazine, which acts locally on the colon’s mucous membrane and has various anti-inflammatory effects, is less effective than glucocorticoids but can be used as a second-line option to induce remission. Methotrexate, a folate derivative that inhibits enzymes responsible for nucleotide synthesis, is the second-line medication used to maintain remission in Crohn’s patients. However, in this case, there is no indication to use second-line management instead of first-line treatment.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

Managing Hypothyroidism: Dosage, Monitoring, and Side-Effects

Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. The main treatment for hypothyroidism is levothyroxine, a synthetic form of thyroid hormone. When managing hypothyroidism, it is important to consider the patient’s age, cardiac history, and initial starting dose. Elderly patients and those with ischaemic heart disease should start with a lower dose of 25mcg od, while other patients can start with 50-100mcg od. After a change in dosage, thyroid function tests should be checked after 8-12 weeks to ensure the therapeutic goal of normalising the thyroid stimulating hormone (TSH) level is achieved. The target TSH range is 0.5-2.5 mU/l.

Women with hypothyroidism who become pregnant should have their dose increased by at least 25-50 micrograms levothyroxine due to the increased demands of pregnancy. The TSH should be monitored carefully, aiming for a low-normal value. It is important to note that there is no evidence to support combination therapy with levothyroxine and liothyronine.

While levothyroxine is generally well-tolerated, there are some potential side-effects to be aware of. Over-treatment can lead to hyperthyroidism, while long-term use can reduce bone mineral density. In patients with cardiac disease, levothyroxine can worsen angina and lead to atrial fibrillation. It is also important to be aware of drug interactions, particularly with iron and calcium carbonate, which can reduce the absorption of levothyroxine. These medications should be given at least 4 hours apart.

In summary, managing hypothyroidism involves careful consideration of dosage, monitoring of TSH levels, and awareness of potential side-effects and drug interactions. With appropriate management, patients with hypothyroidism can achieve normal thyroid function and improve their overall health.

Children born in areas with a high prevalence of tuberculosis (TB) or with parents/grandparents from such areas, as well as individuals under the age of 35 at high risk of occupational exposure to TB, are administered the BCG vaccine. However, there is no evidence to support the effectiveness of the BCG vaccine for individuals over the age of 35, and therefore it is not administered to them.

The BCG Vaccine: Who Should Get It and How It’s Administered

The Bacille Calmette-Guérin (BCG) vaccine is a vaccine that provides limited protection against tuberculosis (TB). In the UK, it is given to high-risk infants and certain groups of people who are at risk of contracting TB. The vaccine contains live attenuated Mycobacterium bovis and also offers limited protection against leprosy.

The Greenbook provides guidelines on who should receive the BCG vaccine. It is recommended for all infants living in areas of the UK where the annual incidence of TB is 40/100,000 or greater, as well as infants with a parent or grandparent who was born in a country with a high incidence of TB. The vaccine is also recommended for previously unvaccinated tuberculin-negative contacts of cases of respiratory TB, new entrants under 16 years of age who were born in or have lived for a prolonged period in a high-risk country, healthcare workers, prison staff, staff of care homes for the elderly, and those who work with homeless people.

Before receiving the BCG vaccine, any person being considered must first be given a tuberculin skin test, except for children under 6 years old who have had no contact with tuberculosis. The vaccine is given intradermally, normally to the lateral aspect of the left upper arm. It can be given at the same time as other live vaccines, but if not administered simultaneously, there should be a 4-week interval.

There are some contraindications for the BCG vaccine, including previous BCG vaccination, a past history of tuberculosis, HIV, pregnancy, and a positive tuberculin test (Heaf or Mantoux). It is not given to anyone over the age of 35, as there is no evidence that it works for people of this age group.

Horner syndrome is a rare condition caused by a disruption of the sympathetic nerve supply to the eye. It is characterized by a triad of symptoms including a constricted pupil, partial drooping of the eyelid, and loss of sweating on one side of the face. Possible causes of Horner syndrome include brain-stem stroke or tumor, brachial plexus trauma, lung infections or tumors, carotid artery issues, and migraines. Multiple sclerosis is an autoimmune disease that attacks the central nervous system and can cause optic neuritis, but the symptoms described in the scenario do not match those of MS. Holmes-Adie syndrome is a neurological disorder characterized by a dilated pupil that reacts slowly to light, loss of deep tendon reflexes, and profuse sweating, which is not consistent with the scenario. Myasthenia gravis is an autoimmune disorder that causes muscle weakness, but it typically affects the facial muscles and extraocular muscles, not the pupil. Riley-Day syndrome is a disorder of the autonomic nervous system that affects infants and is characterized by the absence of overflow tears with emotional crying.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

The use of diclofenac is now prohibited for individuals with any type of cardiovascular ailment.

MHRA Guidance on Diclofenac and Cardiovascular Safety

The MHRA has updated its guidance on diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), after a Europe-wide review of cardiovascular safety. While it has been known for some time that NSAIDs may increase the risk of cardiovascular events, the evidence base has become clearer. Diclofenac is associated with a significantly higher risk of cardiovascular events compared to other NSAIDs. Therefore, it is contraindicated in patients with ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, and congestive heart failure (New York Heart Association classification II-IV). Patients should switch from diclofenac to other NSAIDs such as naproxen or ibuprofen, except for topical diclofenac. Studies have shown that naproxen and low-dose ibuprofen have the best cardiovascular risk profiles of the NSAIDs.

The MHRA’s updated guidance on diclofenac and cardiovascular safety highlights the increased risk of cardiovascular events associated with this NSAID compared to other NSAIDs. Patients with certain conditions are advised to avoid diclofenac and switch to other NSAIDs. This guidance is important for healthcare professionals to consider when prescribing NSAIDs to patients with cardiovascular risk factors.

Obstetric cholestasis, also known as intrahepatic cholestasis of pregnancy, is a condition that occurs when the flow of bile is impaired, resulting in a buildup of bile salts in the skin and placenta. The cause of this condition is believed to be a combination of hormonal, genetic, and environmental factors. While the pruritic symptoms can be distressing for the mother, the buildup of bile salts can also harm the fetus. The fetus’s immature liver may struggle to break down the excessive levels of bile salts, and the vasoconstricting effect of bile salts on human placental chorionic veins may lead to sudden asphyxial events in the fetus, resulting in anoxia and death.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.